Metformin × adverse events & safety

SynthesisBMC medicine2024

Metformin use and preeclampsia risk in women with diabetes: a two-country cohort analysis.

Hannah Gordon et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

No clear link with blood pressure

−12%−34% to +19%

Bigger than 3 in 10 on the map

As reported

RR 0.88, 95% CI 0.66–1.19

Correlation · may be no link

No clear link with blood pressure

+8%−14% to +37%

Bigger than 2 in 10 on the map

As reported

RR 1.08, 95% CI 0.86–1.37

Correlation · may be no link

No clear link with pregnancy & neonatal

+2%−34% to +60%

Smaller than almost all on the map

As reported

RR 1.02, 95% CI 0.66–1.60

+5 more in the walkthrough ↓

Eight numbers in the abstract

the abstract, start to end

(Scotland adjusted relative risk (aRR) 0.88 [95% confidence interval (CI) 0.66-1.19]; Sweden aRR 1.08 [95% CI 0.86-1.37]) or preeclampsia (Scotland aRR 1.02 [95% CI 0.66-1.60]; Sweden aRR 1.00 [95% CI 0.72-1.39]).

outcomes, including preterm birth (RR 1.00 [95% CI 0.89-1.13]), and birthweight < 10th percentile (RR 0.82 [95% CI 0.60-1.13]) or < 3rd percentile (RR 0.78 [95% CI 0.41-1.48]).

of birthweight > 4500 g in Scotland (aRR 0.39 [95% CI 0.21-0.71]) but not in

← favours treatmentfavours comparator →
could be chance
Blood pressure
RR 0.880.66–1.19
Blood pressure
RR 1.080.86–1.37
Pregnancy & neonatal
RR 1.020.66–1.60
Pregnancy & neonatal
RR 1.000.72–1.39
Adverse events & safety
RR 1.000.89–1.13
Pregnancy & neonatal
RR 0.820.60–1.13
Pregnancy & neonatal
RR 0.780.41–1.48
Pregnancy & neonatal
RR 0.390.21–0.71
MetforminBlood pressurePregnancy & neonatalAdverse events & safety
1 / 3

2 papers cite it

2024
2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 39334302